Institutional shares held 151 Million
195K calls
53.2K puts
Total value of holdings $11B
$14.2M calls
$3.87M puts
Market Cap $2.85B
39,222,600 Shares Out.
Institutional ownership 384.95%
# of Institutions 602


Latest Institutional Activity in TECH

Top Purchases

Q3 2024
Point72 Asset Management, L.P. Shares Held: 1.12M ($81.7M)
Q3 2024
Citadel Advisors LLC Shares Held: 1.2M ($87.6M)
Q3 2024
Price T Rowe Associates Inc Shares Held: 9.42M ($686M)
Q3 2024
Adage Capital Partners Gp, L.L.C. Shares Held: 324K ($23.5M)
Q3 2024
Invesco Ltd. Shares Held: 3.46M ($252M)

Top Sells

Q3 2024
Select Equity Group, L.P. Shares Held: 1.84M ($134M)
Q3 2024
Arrow Mark Colorado Holdings LLC Shares Held: 709K ($51.5M)
Q3 2024
Allspring Global Investments Holdings, LLC Shares Held: 657K ($47.8M)
Q3 2024
Bamco Inc Shares Held: 4.45M ($323M)
Q3 2024
Brown Capital Management LLC Shares Held: 2.11M ($153M)

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.


Insider Transactions at TECH

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
173K Shares
From 14 Insiders
Grant, award, or other acquisition 12.4K shares
Exercise of conversion of derivative security 161K shares
Sell / Disposition
116K Shares
From 8 Insiders
Payment of exercise price or tax liability 85.8K shares
Open market or private sale 30.4K shares

Track Institutional and Insider Activities on TECH

Follow BIO-TECHNE Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TECH shares.

Notify only if

Insider Trading

Get notified when an Bio Techne Corp insider buys or sells TECH shares.

Notify only if

News

Receive news related to BIO-TECHNE Corp

Track Activities on TECH